WUXI BIOLOGICS UNSP/ADR

The widespread adoption of single-use bioreactors in the biopharmaceutical industry is driven by their adaptability, efficiency, and reduced risk of cross-contamination, leading to enhanced product safety and quality. The market is expected to grow significantly, with North America dominating the global market.

Related tickers: GNGBY, WXXWY, SSSGY, MKKGY, TMO, SRTOY.

Aadi Bioscience announced it filed a definitive proxy statement and scheduled a special meeting of stockholders for February 28, 2025 to vote on the sale of FYARRO to Kaken Pharmaceuticals for $100 million, the in-licensing of a portfolio of antibody drug conjugates from WuXi Biologics, and a $100 million PIPE financing.

Related tickers: AADI, WXXWY.